Tim Jansen

ORCID: 0000-0003-3026-3154
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gout, Hyperuricemia, Uric Acid
  • Rheumatoid Arthritis Research and Therapies
  • Case Reports on Hematomas
  • Spondyloarthritis Studies and Treatments
  • Urticaria and Related Conditions
  • Systemic Lupus Erythematosus Research
  • Inflammasome and immune disorders
  • Autoimmune and Inflammatory Disorders Research
  • Sarcoidosis and Beryllium Toxicity Research
  • Systemic Sclerosis and Related Diseases
  • Chronic Lymphocytic Leukemia Research
  • Musculoskeletal synovial abnormalities and treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Hepatitis C virus research
  • Hematological disorders and diagnostics
  • Streptococcal Infections and Treatments
  • Lymphoma Diagnosis and Treatment
  • Orthopedic Surgery and Rehabilitation
  • Liver Disease Diagnosis and Treatment
  • Veterinary medicine and infectious diseases
  • Celiac Disease Research and Management
  • Immunodeficiency and Autoimmune Disorders
  • Inflammatory Myopathies and Dermatomyositis
  • Biosimilars and Bioanalytical Methods
  • Bone and Joint Diseases

VieCuri Medisch Centrum
2016-2025

Utrecht University
2024

University Medical Center Utrecht
2024

University of Twente
2015-2024

Center for Rheumatology
2001-2024

Janssen (United States)
2020-2021

Expert System (Italy)
2020

Radboud University Nijmegen
1996-2016

Rijnstate Hospital
1991-2016

Radboud University Medical Center
2009-2016

Objectives To agree terminology and to develop recommendations for the diagnosis of calcium pyrophosphate deposition (CPPD). Methods The European League Against Rheumatism (EULAR) CPPD Task Force, comprising 15 experts from 10 countries, agreed terms using a Delphi consensus approach. Evidence was systematically reviewed presented in sensitivity, specificity positive likelihood ratio (LR) support diagnosis; ORs were used association. Strength recommendation (SOR) assessed by EULAR visual...

10.1136/ard.2010.139105 article EN Annals of the Rheumatic Diseases 2011-01-07

Although gout is the most common inflammatory arthritis, it still frequently misdiagnosed. New data on imaging and clinical diagnosis have become available since first EULAR recommendations for of in 2006. This prompted a systematic review update 2006 recommendations. A literature concerning all aspects was performed. Recommendations were formulated using Delphi consensus approach. Eight key generated. search crystals synovial fluid or tophus aspirates recommended every person with suspected...

10.1136/annrheumdis-2019-215315 article EN Annals of the Rheumatic Diseases 2019-06-05

The study of the proinflammatory role uric acid has focused on effects its crystals monosodium urate (MSU). However, little is known whether itself can directly have effects. In this study, we investigate priming exposure cytokine production primary human cells upon stimulation with gout-related stimuli.Peripheral blood mononuclear (PBMCs) were harvested from patients gout and healthy volunteers. Cells pretreated or without in soluble form for 24 h then stimulated toll-like receptor (TLR)2...

10.1136/annrheumdis-2014-206564 article EN Annals of the Rheumatic Diseases 2015-02-03

Objectives To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). Methods A multidisciplinary guideline development group 15 experts, representing 10 European countries, generated key propositions CPPD using a Delphi consensus approach. For each recommendation research evidence was searched systematically. Whenever possible, the effect size and number needed to treat efficacy RR or OR side effects were calculated individual treatment modalities....

10.1136/ard.2010.139360 article EN Annals of the Rheumatic Diseases 2011-01-20

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) EULAR have developed the first‐ever CPPD disease. Methods Supported by ACR EULAR, a multinational group investigators followed established methodology to develop these criteria. generated lists candidate items refined their definitions, collected de‐identified patient...

10.1002/art.42619 article EN cc-by-nc Arthritis & Rheumatology 2023-07-26

Untreated gout is characterised by monosodium urate (MSU) crystal accumulation responsible for recurrent flares that are commonly separated asymptomatic phases. Both phases inflammatory conditions of variable intensity. Gout self-limited reactions involving multiple mediators. This study aimed to characterise the profiles at different

10.1136/ard-2023-225305 article EN Annals of the Rheumatic Diseases 2024-02-19

Identifying ankylosing spondylitis (AS) patients who are likely to benefit from tumor necrosis factor-alpha (TNF-α) blocking therapy is important, especially in view of the costs and potential side effects these agents. Recently, AS Disease Activity Score (ASDAS) has been developed assess both subjective objective aspects disease activity. However, data about predictive value ASDAS with respect clinical response TNF-α lacking. The aim present study was identify baseline predictors...

10.1186/ar3369 article EN cc-by Arthritis Research & Therapy 2011-06-20

<h3>Objectives:</h3> To compare the efficacy and tolerability of allopurinol 300–600 mg/day versus benzbromarone 100–200 used to attain a target serum urate concentration (sUr) ⩽0.30 mmol/l (5 mg/dl). <h3>Methods:</h3> A randomised, controlled, open-label, multicentre trial in gout patients with renal function defined as calculated creatinine clearance ⩾50 ml/min. Patients were treated 300 mg or 100 once day (stage 1). If sUr was not attained after 2 months, dose doubled twice 200 2). The...

10.1136/ard.2008.091462 article EN Annals of the Rheumatic Diseases 2008-07-16

Objectives: To investigate the efficacy and tolerability of allopurinol as first-choice antihyperuricaemic treatment for gout, compare benzbromarone probenecid second-choice treatment. Methods: Prospective, multicentre, open-label, two-stage randomised controlled trial in gout patients with normal renal function. Enrolled were given 300 mg 2 months (stage 1). Those who could not tolerate or did attain target serum urate concentration (sUr) ⩽0.30 mmol/l (5.0 mg/dl), which was defined...

10.1136/ard.2007.083071 article EN Annals of the Rheumatic Diseases 2008-02-04

Objective To determine which clinical, laboratory, and imaging features most accurately distinguished gout from non‐gout. Methods We performed a cross‐sectional study of consecutive rheumatology clinic patients with ≥1 swollen joint or subcutaneous tophus. Gout was defined by synovial fluid tophus aspirate microscopy certified examiners in all patients. The sample randomly divided into model development (two‐thirds) test (one‐third). Univariate multivariate association between clinical...

10.1002/acr.22585 article EN Arthritis Care & Research 2015-03-16

Objective To examine the performance of ultrasound (US) for diagnosis gout using presence monosodium urate monohydrate (MSU) crystals as gold standard. Methods We analyzed data from Study Updated Gout Classification Criteria (SUGAR), a large, multicenter observational cross‐sectional study consecutive subjects with at least 1 swollen joint who conceivably may have gout. All underwent arthrocentesis; cases were confirmed MSU crystals. Rheumatologists or radiologists blinded regard to results...

10.1002/art.39959 article EN Arthritis & Rheumatology 2016-10-17

Objectives Acute gouty arthritis is caused by endogenously formed monosodium urate (MSU) crystals, which are potent activators of the NLRP3 inflammasome. However, to induce release active interleukin (IL)-1β, an additional stimulus needed. Saturated long-chain free fatty acids (FFAs) can provide such a signal and stimulate transcription pro-IL-1β. In contrast, short-chain acid butyrate possesses anti-inflammatory effects. One mechanisms involved inhibition histone deacetylases (HDACs). Here,...

10.1136/annrheumdis-2014-206258 article EN Annals of the Rheumatic Diseases 2015-01-14

To evaluate the efficacy and safety of anakinra in treating acute gout flares a randomized, double-blind, placebo-controlled, active comparator, non-inferiority (NI) trial.

10.1093/rheumatology/key402 article EN Lara D. Veeken 2018-11-16

<h3>Objective</h3> There is a lack of standardisation in the terminology used to describe gout. The aim this project was develop consensus statement describing recommended nomenclature for disease states <h3>Methods</h3> A content analysis gout-related articles from rheumatology and general internal medicine journals published over 5-year period identified potential labels commonly assigned them. Based on these findings, experts gout were invited participate Delphi exercise face-to-face...

10.1136/annrheumdis-2019-215933 article EN Annals of the Rheumatic Diseases 2019-09-09

Objective The language currently used to describe gout lacks standardization. aim of this project was develop a consensus statement on the labels and definitions basic disease elements gout. Methods Experts in (n = 130) were invited participate Delphi exercise face‐to‐face meeting reach labeling for Disease current use derived from content analysis contemporary medical literature, results item selection meeting. Results There 51 respondents 30 attendees at Consensus agreement (≥80%) achieved...

10.1002/acr.23607 article EN Arthritis Care & Research 2018-05-25

Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) EULAR have developed the first-ever CPPD disease.Supported by ACR EULAR, a multinational group investigators followed established methodology to develop these criteria. generated lists candidate items refined their definitions, collected de-identified patient profiles,...

10.1136/ard-2023-224575 article EN Annals of the Rheumatic Diseases 2023-07-26
Coming Soon ...